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Abstract
Background: To address evolution of HIV-1 after transmission, we studied sequence dynamics in and outside predicted
epitopes of cytotoxic T lymphocytes (CTL) in subtype B HIV-1 variants that were isolated from 5 therapy-naive horizontal
HLA-disparate donor-recipient pairs from the Amsterdam Cohort Studies on HIV-1 infection and AIDS.
Methodology/Principal Findings: In the first weeks after transmission, the majority of donor-derived mutations in and
outside donor-HLA-restricted epitopes in Gag, Env, and Nef, were preserved in the recipient. Reversion to the HIV-1 subtype
B consensus sequence of mutations in- and outside donor-HLA-restricted CTL epitopes, and new mutations away from the
consensus B sequence mostly within recipient-HLA-restricted epitopes, contributed equally to the early sequence changes.
In the subsequent period (1–2 years) after transmission, still only a low number of both reverting and forward mutations
had occurred. During subsequent long-term follow-up, sequence dynamics were dominated by forward mutations, mostly
(50–85%) in recipient-HLA-restricted CTL epitopes. At the end of long-term follow-up, on average 43% of the transmitted
CTL escape mutations in donor-HLA-restricted epitopes had reverted to the subtype B consensus sequence.
Conclusions/Significance: The relatively high proportion of long-term preserved mutations after transmission points to a
lack of back selection even in the absence of CTL pressure, which may lead to an accumulating loss of critical CTL epitopes.
Our data are supportive for a continuous adaptation of HIV-1 to host immune pressures which may have implications for
vaccine design.
Citation: Navis M, Edo Matas D, Rachinger A, Koning FA, van Swieten P, et al. (2008) Molecular Evolution of Human Immunodeficiency Virus Type 1 upon
Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs. PLoS ONE 3(6): e2422. doi:10.1371/journal.pone.0002422
Editor: Olivier Schwartz, Institut Pasteur, France
Received February 28, 2008; Accepted April 30, 2008; Published June 18, 2008
Copyright:  2008 Navis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MN is financially supported by Landsteiner Foundation for Blood Transfusion Research (grant 0317), DEM is financially supported by the Netherlands
AIDS fund (grant 6006) and the Sanquin Netherlands Blood Supply Foundation, AR is supported by Academic Medical Center Amsterdam, FAK and NK are
financially supported by The Netherlands Organization for Scientific Research (grants 901-02-222 and 916.36.024, respectively). None of the funders of the here
described study had a role in the design or conduct of the study, nor in the collection, analysis, or interpretation of the data, and also not in the preparation,
review, or approval of the manuscript. The Amsterdam Cohort Studies are financially supported by the Netherlands National Institute for Public Health and the
Environment.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: h.schuitemaker@amc.uva.nl
¤ Current address: Department of Infectious Diseases, King’s College London School of Medicine, London, United Kingdom
Introduction
CD8+ T cell responses play an important role in the control of
replication of HIV in humans and of simian immunodeficiency
virus (SIV) in rhesus macaques [1,2]. In the acute phase of
infection, control of HIV-1 and SIV viremia has been correlated
with the appearance of virus specific CD8
+ T cells [2–5] and
depletion of CD8+ T cells during the chronic phase of SIV
infection was associated with a rise in viral load, implicating the
importance of CD8+ T cells in controlling SIV replication [5].
HIV-and SIV infection are characterized by the presence of
multiple variants within individuals [6–9]. This diversity is a
consequence of high viral turnover, high viral reverse-transcriptase
(RT) error rate, recombination, and selective pressures exerted by
the host’s immune system, including CD8
+ T cell responses [10–
12]. Indeed, the generation of 10
8–10
9 new viral particles per day
in chronically infected individuals [13,14] creates an environment
in which, in the presence of immune selection pressure exerted by
CD8
+ T cells, a large number of CD8
+ T cell escape variants
should be selected every day.
Evasionofthe host CD8+ T cellresponsesisindeeda majorfactor
influencing the evolution of HIV-1. The CD8+ Tc e l lr e p e r t o i r eh a s
the potential to detect many small peptide sequences encoded
throughout the HIV-1 genome. Evasion of CD8+ Tc e l lr e s p o n s e s
involves mutations within and outside targeted epitopes that can
result in the inability of the peptide to bind to Class I MHC, the loss
of recognition of the epitope by the CD8+ T cell receptor, or
interference with peptide processing [15–19].
HIV-1 and SIV escape from CD8
+ T cell recognition has been
well documented in the acute and chronic phases of HIV-1 and
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emergence of viral escape mutations preceded rapid disease
progression [12,23–25].
Transmission of viral escape variants to a new host has been
documented in both horizontal and vertical HIV-1 infections [18,26–
30]. The persistence of CD8
+ T cell escape variants of HIV-1 after
transmission may depend on the balance between CD8
+ Tc e l l –
mediated selective pressures and cost to viral replication fitness.
Indeed, reversion to wild-type sequence will most likely occur if the
escape mutation is associated with at least some replication fitness cost
for the virus [31] and provided that the escape variant is transmitted
to a non–HLA-matched recipient in whom similar CD8
+ Tc e l l
selective pressures on that same epitope will not be elicited.
To date, post-transmission reversions of CTL escape mutations
have been studied in the SIV macaque model [32] and for HIV-1
mainly in the highly conserved Gag region [33,34], and in epitopes
that are restricted by protective HLA-B57 alleles in the virus donor
[27] or in situations where the HLA type of the donor, and thus
the position of CTL escape mutations, was not known [35].
Here,westudiedviralgag,env,andnefsequencesofclonalHIV-1
variantsthatwereisolatedfrom5HIV-1 donorscloseto the moment
of HIV-1 transmission and at multiple timepoints after seroconver-
sion from their HLA disparate recipients who participate in the
Amsterdam Cohort Studies on HIV infection and AIDS.
Results
HLA disparate donor-recipient pairs
To analyze the dynamics of potential CTL escape mutations in
donor-HLA-restricted epitopes after transmission, we studied
sequence changes in HIV-1 variants isolated from known HLA
disparate donor-recipient pairs(Table 1 and 2). Deduced amino acid
(AA) sequences from Gag (AA position 90–340), Env (gp120, AA
position 80–510), and Nef (AA position 1–180) were generated from
clonal virus variants that were isolated from donors and recipients at
time points as closely as possible to the HIV-1 transmission event.
From donor D5 HIV-1 variants were additionally isolated
28 months after transmission. From all recipients additional clonal
HIV-1 variants were isolated between 9 and 22 months from a time
point 54–112 months after transmission.
Phylogenetic analysis of Env sequences demonstrated that HIV-
1 variants from reported transmission couples grouped together in
a phylogenetic tree indicating that transmission between partners
was indeed highly likely (Supplementary Figure S1).
Availability of the HLA-A and –B typing from the donors and
the Gag, Env, and Nef sequences from their viruses allowed an
accurate estimation of AA differences within and outside predicted
HLA-restricted-epitopes relative to the HIV-1 subtype B consen-
sus sequence from the Los Alamos Database (http://www.HIV-1.
lanl.gov). Amino acids that changed into a residue identical to the
HIV-1 subtype B consensus for that position were considered
reversions. Sequence changes away from the HIV-1 subtype B
consensus, including escape mutations in predicted CTL epitopes
restricted by the HLA type of the recipient, were considered
forward mutations.
Epitopes for subtype A*2301 (expressed by donors D2 and D3),
B*49 (also expressed by donor D3), and A*3604 (expressed by
recipient R4) were not available in the Los Alamos Database. To
avoid an overestimation of the number of epitopes in the viruses
from these donors we only used their other HLA types for the
prediction of CTL epitopes.
Reversion of mutations towards the HIV-1 subtype B
consensus sequence upon viral transmission between
HLA disparate donor-recipient pairs
First we calculated the number of AA differences relative to the
HIV-1 subtype B consensus sequence in clonal HIV-1 variants
isolated from the donors at a time point as closely as possible to the
transmission event. Mutations in predicted epitopes that were
restricted by the donor HLA type were considered potential CTL
escape mutations (Fig 1, left panels, donor). The earliest recipient
viruses were then studied for preservation of AA differences, within
or outside predicted donor-HLA restricted-epitopes, that we had
first identified in the donor viruses (Figure 1, left panels, recipient).
The majority of AA differences that were present in HIV-1
variants from the donor were still present in HIV-1 variants that
were isolated from the recipient within 2–3 weeks after the
transmission event (Figure 1, left panels, ‘‘transmitted’’).
Amino acid differences relative to the consensus B sequence,
that were present in donor viruses, but absent in the earliest
recipient viruses were considered to have reverted within the first
2–3 weeks after transmission. In HIV-1 variants from donors D1–
D5, we observed a total of respectively 41, 58, 45, 43, and 46 AA
differences in Gag, Env, and Nef, relative to the HIV-1 subtype B
consensus sequence for these genes (Figure 1, left panel). Only 1, 5,
0, 2 and 4 AA changes, respectively per donor, were at anchor
residue positions (Supplementary Table S1).
Of all AA differences in Gag, Env, and Nef, only 0, 1, 7, 10, or
20, respectively, had reverted in viruses isolated from the recipients
early after transmission and less than 50% of these reversions were
in predicted epitopes restricted by the HLA type of the donor
(Figure 1, right panels, black stacks).
In HIV-1 variants isolated from all recipients 9–22 months after
the transmission event, a limited number of additional reversions
had occurred, again both in- and outside predicted donor-HLA-
restricted epitopes (Figure 1, right panels, white stacks).
At the end of follow-up (54–112 months after transmission)
HIV-1 variants isolated from recipients R1 to R5 revealed
respectively 4, 13, 23, 7, and 2 additional reversions of which
only 0, 6, 5, 2 and 0 were in predicted donor-HLA-restricted
epitopes (Figure 1, right panels, hatched stacks).
Amino acid differences relative to the consensus B sequence that
were present in donor viruses, and still present in recipient viruses
isolated at the end of follow-up (54–112 months after transmis-
Table 1. HLA typing of donors and recipients involved in HIV-
1 transmission.
Patient
Date of seroconversion
(SC) or seroprevalent
entry (SP) in cohort HLA type
D1 05-08-1987 (SC) A*01, A*24, B*07, B*07
R1 28-11-1988 (SC) A*0201, A*3004, B*1401, B*5108
a
D2 23-01-1985 (SP) A*2301
a, A*3301, B*7801, B*1503
R2 28-10-1986 (SC) A*0201, A*1101, B*4001, B*5201
D3 04-02-1985 (SP) A*2301
a, A*0101, B*40, B*49
a
R3 08-05-1987 (SC) A*24, A*26, B*27, B*0801
D4 07-03-1988 (SP) A*01, A*03, B*07, B*08
R4 25-09-1986 (SC) A*3604
a, A*0201, B*0801, B*40
D5 24-02-1988 (SP) A*0201, A*3201, B*07, B*35
R5 05-01-1987 (SC) A*0207, A*0207, B*0801, B*27
aEpitopes for subtypes A
*2301, A
*3604 and B
*49 were not available in the Los
Alamos database and therefore for these individuals only the other HLA
epitopes were used for prediction of epitopes. D: donor; R: recipient
doi:10.1371/journal.pone.0002422.t001
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(Figure 1, left panels, recipient).
Overall, the number of reversions was low and predominantly
outside predicted CTL epitopes restricted by the HLA type of the
donor. The exact AA residues within predicted CTL epitopes that
are restricted by the donor-HLA type and the AA residues that
reverted to the HIV-1 subtype B consensus sequence in viruses
isolated from the recipient are shown in Supplementary Table S1.
Forward mutations in HIV-1 in recently infected
individuals
Next we calculated the number of forward mutations that
occurred within and outside predicted CTL epitopes restricted by
the HLA-type of the recipients, in viral sequences from clonal
HIV-1 variants that were isolated at relatively early, intermediate,
and late time points after transmission from all recipients (Figure 1,
right panels).
During the first 2–3 weeks after transmission, viruses from
recipients R1 to R5 showed 7, 1, 5, 4, and 9 forward mutations,
the majority of which in predicted recipient-HLA-restricted CTL
epitopesb (Figure 1, right panel, black stacks).
In HIV-1 variants that were isolated at the intermediate time
point (range 9 to 22 months after transmission) from R1-R5, a
total of 11, 5, 0, 8 and 4 forward mutations had accumulated, the
majority of which again in predicted recipient-HLA-restricted
CTL epitopes.
Attheendoffollow-up(54–112 monthsaftertransmission),atotal
of 14, 40, 56, 28 and 30 forward mutations had accumulated in
HIV-1 variants from recipients R1 to R5 respectively. Of these
mutations, the majority(7, 34, 44, 22,and 18,respectively for viruses
fromR1–R5)wereinpredictedrecipient-HLA-restrictedepitopes,of
which respectively 2, 10, 12, 6 and 8 were at anchor residue
positions. An overview of the exact AA residues in predicted CTL
epitopes restricted by the recipient’s HLA types that mutated away
from the HIV-1 subtype B consensus sequence in viruses isolated
from the recipient is shown in Supplementary Table S1.
Dynamics of HIV-1 sequences upon transmission
between HLA disparate donor-recipient pairs
HIV-1 virus variants from all donors showed the lowest number
of AA differences with the subtype B consensus in Gag and the
highest number of differences in Env, confirming their respective
highly conserved and variable nature. A similar observation was
made in HIV-1 variants from all recipients in which the number of
forward mutations was the highest in Env and Nef.
In summary, the donors of our 5 horizontal transmission pairs
harbored HIV-1 variants that contained a total of 233 AA
differences relative to the HIV-1 subtype B sequence, of which 93
(40%) AA differences were in predicted donor-HLA-restricted
epitopes. In HIV-1 variants isolated from the recipients early after
the transmission event, a total of 188 AA (81%) differences were
still present of which 72 (38%) were in epitopes restricted by the
HLA type of the donor. Of the 20 AA differences that had rapidly
reverted in the recipient, 14 (70%) were in donor-HLA-restricted
epitopes and equally distributed over Gag, Env, and Nef genes.
Throughout the subsequent follow-up period, which varied
from 9 to 22 months after transmission between recipients, we
found similar ratios of reverting and forward mutations, although
total numbers of AA changes were low (Ratio reversion/forward
mutations for R1: 5/11; R2: 2/5; R3: 3/0; R4: 1/8; R5: 4/4).
During the subsequent follow-up period of 54–112 months after
transmission, sequence evolution in HIV-1 variants from all
recipients was dominated by forward mutations (Ratio reversion/
forward mutations R1: 4/14; R2: 13/39; R3: 23/56; R4: 7/27;
R5: 2/29). In this later phase of infection, 54–100% of reversions
were outside predicted donor-HLA-restricted epitopes, while the
majority of all forward mutations (50–85%) had occurred inside
predicted recipient-HLA-restricted epitopes.
Table 2. Characteristics of donors and recipients involved in HIV-1 transmission
Donor
Time point
of analysis
a
(weeks)
CD4
(cells/ml)
Plasma load
(log copies/ml)
Number
of clones
analysed Recipient
Time point
of analysis
(months)
CD4
(cells/ml)
Plasma load
(log copies/ml)
Number of
clones
analysed
D1 0 500 5.60 5 R1 0.75 670 3.00 2
18 580 4.26
b 10
54 450 5.43 4
D2 223 1100 4.46 4 R2 0.5 720 3.00
b 2
14.25 1150 4.67
b 5
112.2 100 5.71 3
D3 4 460 4.67 5 R3 0.75 590 4.52
b 2
9 960 3.95
b 1
107.5 500 3.00 2
D4 77 380 4.81 5 R4 0.75 950 5.84 5
18 490 4.34
b 2
95.8 620 4.20 3
D5 102 600 4.79 5 R5 0.75 370 4.08
b 2
126 470 4.64 5 22 330 3.76 4
97.8 80 4.92 4
aWeeks prior to or after seroconversion of the recipient
bPlasma load determined 3 months before the time point of virus isolation
doi:10.1371/journal.pone.0002422.t002
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biological cloned HIV-1 variants
Finally, we analyzed whether the sequence dynamics as observed
in the longitudinally isolated clonal HIV-1 variants were represen-
tative for HIV-1 sequence changes in plasma. To this end we
compared sequences of the Env V3V4 region of the clonal HIV-1
variants of all recipients with sequences from the V3V4 region from
HIV-1 RNA in plasma from the same or similar time points.
Confirming the close relation between the viral quasispecies in
plasma and in productively infected cells, all reversions and
forward mutations that had been observed in- and outside
predicted CTL epitopes in V3V4 of the clonal HIV-1 variants
were also present in viral RNA sequences from plasma (data not
shown). The identical sequence dynamics in the V3V4 Env region
of the clonal HIV-1 variants studied here and in the viral RNA in
plasma suggest that the sequence dynamics observed in our
longitudinally obtained clonal HIV-1 variants are a true reflection
of the sequence dynamics in vivo.
Discussion
In this study, we analyzed sequence evolution of HIV-1 in 5
recipients of HLA-disparate HIV-1 transmission pairs that
participate in the Amsterdam Cohort Studies on HIV-1 infection
and AIDS. We isolated multiple clonal HIV-1 variants from
productively infected cells throughout the course of infection and
analyzed sequence evolution in Gag, Env and Nef. This allowed us
not only to study virus evolution in recipients and their donors, but
also to compare sequence evolution in different genes.
In agreement with a recent study that also focused on viral
evolution in the first months to years after HIV-1 infection [35],
we observed a considerable number of mutations already very
early after seroconversion. In that study, however, early sequence
evolution was dominated by reversions while in our study [35],
reversions and forward mutations contributed equally to the early
sequence dynamics in HIV-1.
In analogy to previous studies [28,35], we determined sequence
differences relative to the HIV-1 subtype B consensus sequence
from the LANL HIV Sequence Database {REF}. Furthermore,
availability of sequences from both donor and recipient virus
populations allowed us to accurately calculate the number of
transmitted AA differences that subsequently reverted in recipient
viruses, both in and outside CTL epitopes restricted by the HLA-
type of the donor. We used predicted epitopes rather than epitopes
for which CTL reactivity was actually demonstrated [36] as to
prevent a bias in our analyses towards better investigated HIV-1
genes (Gag) and HLA types (HLA A*02, B*57 and B*27). The
observation that for the vast majority of predicted epitopes CTL
recognition has indeed been demonstrated [37] supports our
approach. Moreover, when we based our epitope mapping on a
recent comprehensive collection of reported epitopes by Frahm
and Brander [36], similar to the approach of Li et al [35], we still
observed a similar contribution of forward and reverting mutations
to the early sequence dynamics (data not shown). The limit of this
latter approach, however, is that a much lower number of
mutations can be interpreted as potential CTL escape mutation.
Based on the observation that CTL escape mutations revert
upon transmission [27,32,35] Leslie et al. were the first to conclude
that this may be driven by a gain of fitness, implying that at least
some CTL escape mutations come at a substantial fitness cost [27].
They monitored the T242N mutation in the HLA-B57 restricted
TW10 epitope during mother-to-child transmission. The N242T
reversion was observed when the virus was transmitted from an
HLA-B57 positive mother to an HLA-B57 negative child while the
242N residue was conserved when the virus was transmitted to an
HLA-B57 matched child. In agreement with the hypothesis that
reversion of mutations is driven by gain of fitness, Li et al. observed
that reverting mutations preferentially arose within highly
conserved residues and suggested that the severity of fitness loss
associated with CTL escape mutations, so the strength of back
selection, determines the kinetics by which escape mutations and
reversions occur [38]. A recent study has shown that non-
transmission or reversion after transmission was associated with
reduced fitness thereby in support of the notion that some escape
mutations come at a fitness cost. However, that study again only
focused on the highly conserved p17 and p24 in Gag [39].
In our study, even the limited number of very early reversions
were not restricted to highly conserved regions but equally
distributed in Gag and Env although the number of mutations in
Gag in donor virused was low. It cannot be excluded that the donor
virus population in the study by Li et al. had substantially more
mutations in the conserved Gag region which could relate to the
HLA type of the donor. Unfortunately, this information was not
available as in that study virus donors were not known. Nevertheless,
if rapid reversion of mutations is considered to reflect the severity of
the fitness cost associated with these mutations, our data seem to
suggest that CTL escape mutations outside conserved regions may
also be associated with a severe fitness cost to the virus.
Our sequence analysis was performed on clonal HIV-1 variants
isolated from single productively infected cells as this allows the
comparison of sequence dynamics in different genes of a single
virus variant. Even though clonal virus isolation does not suffer
from the competitive selection bias of bulk cultures, a point of
concern of working with cultured viruses is that the observed AA
reversions may not have occurred in the recipient but during the
virus isolation procedure. However, a 5 months culture of 2 donor
and 3 recipient virus variants in 96 replicates per virus, resulted in
a maximum of only 2 random nucleotide changes in the V3/V4
region in 50 to 100% of the microcultures per virus variant (data
not shown), indicating that it is highly unlikely that during the
short term culture for virus isolation any reversions have occurred.
AnotherconcernmaybethattheseclonalHIV-1variantsmaynot
be fully representative of the total, replication competent viral
quasispecies in plasma. However, AA changes in the Env V3V4
Figure 1. Absolute number of AA differences relative to the consensus HIV-1 subtype B sequence in HIV-1 Gag, Env and Nef from 5
donor-recipient pairs (a–e). Left panels: Based on the HLA types of donors we determined if AA differences were inside (white bars) or outside
(black bars) predicted CTL epitopes. We distinguished AA differences that were present in the donor (donor), that were still present early after
transmission to the recipient (transmitted) and that were still present in recipient viruses after long-term follow-up (long-term persisting) (a–e left
panel). Right panels: Based on the HLA types of the donors, we determined AA residues that were lost in the recipient immediately after
transmission (reversions after 2–3 weeks, black stacks), that reverted during the first years after SC (reversions after 9–22 months, white stacks),o r
that had reverted by the end of follow-up (reversions after 54–112.2 months, hatched stacks). In predicted recipient-HLA-restricted epitopes the
number of mutations was determined directly after SC (forwards after 2–3 weeks, black stacks), during the first years (forwards after 9–22 months,
white stacks), or after long-term follow-up (forwards after 54–112.2 months, hatched stacks). In and out refer to mutations inside and outside
predicted epitopes restricted by donor-HLA in the category ‘‘reversions’’ and by recipient-HLA in the category ‘‘forwards’’.
doi:10.1371/journal.pone.0002422.g001
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identical to AA changes in the V3V4 region in viral RNA in plasma
from the same individuals. Moreover, phylogenetic analysis of env
sequences shows that the viral quasispecies in plasma and isolated
replicationcompetentclonalHIV-1variantsfromsimilartimepoints
from the same individual are very closely related (Navis et al.
manuscript in preparation). Finally, it has been shown that the
kinetics of viral load changes and the emergence of drug resistance
mutations in plasma/serum and productively infected cells are
highly correlated [40–42].
During the intermediate follow-up period that varied from 9 to
22 months after transmission between recipients, we found only
one reverting mutation and very few forward mutations in Gag
while in Env and Nef the numbers of AA reversions and forward
mutations were somewhat higher albeit still low. Only during the
last follow-up period (54–112 months after transmission) sequence
evolution was dominated by forward mutations that mainly
occurred in epitopes restricted by recipient HLA. Interestingly,
in 4 of 5 recipients, the proportion of forward mutations in Env
was much higher within than outside predicted CTL epitopes
indicating that CTL pressure in Env is stronger than other
selections pressures at that stage of infection. Moreover, reversions
constituted nearly half of all AA differences in regions outside
donor-HLA-restricted epitopes. It is tempting to speculate that
these reversions involve AA residues that were selected in the
donor to compensate for loss of fitness associated with CTL escape
mutations [27,43–46]. With reversion of the CTL mutations in the
recipient, apparently some of these compensatory mutations give a
fitness cost themselves, driving their reversion.
At the end of long-term follow-up, on average 43% of the
transmitted CTL escape mutations in donor-HLA-restricted
epitopes had reverted to the consensus sequence in viruses isolated
from the recipient. Although our data confirm that intrapatient
viral evolution driven by CTL pressure does not necessarily
translate to the evolution of HIV-1 at the population level, more
then half of the AA differences that originally occurred in the
donor were still preserved later in the course of infection in the
recipient, in agreement with a previous study [43].
The reversion of escape mutations in epitopes in less conserved
regions of the virus is in line with many studies that have shown the
presence of CTL directed against those regions [47–49] and with
previous studies that have shown evolution towards an ancestral, or
consensus sequence, upon transmission to a new host [35,50]. Had
these epitopes been permanently negatively selected, these CTL
could not have been elicited in later years of the HIV-1 pandemic.
The only slow reversion of mutations in the phase of infection when
recipient CTL are already elicited confirm that a vaccine should not
be based on the HIV-1 consensus sequence but rather should take
into account all possible variation in a given epitope. Fortunately,
this variation may be more limited than previously assumed [51]
which may make it feasible to design a vaccine capable of eliciting
effective HIV-1 specific cellular immune responses.
Materials and Methods
Patients
Five HIV-1 donor-recipient pairs were selected for this study.
Donor-recipient pairs ACH18814-ACH18766 (donor 1 (D1)-
recipient 1 (R1)), ACH19545-ACH18860 (D2-R2), ACH19500-
ACH18829 (D3-R3) participated in the Amsterdam Cohort
Studies on HIV-1 infection and AIDS (http://www.amsterdam-
cohortstudies.org) and entered the cohort studies with a discordant
serostatus for HIV-1 antibodies. HIV-1 transmission occurred
during active follow-up. From donor-recipient pairs ACH11686
(D4)-ACH19342 (R4) and ACH13994 (D5)-ACH18839 (R5),
initially only the recipients participated in the cohort studies and
seroconverted for HIV-1 antibodies during active follow-up. Their
HIV-1-positive sexual partners were asked to participate in the
cohort studies after the HIV-1 transmission event. Recipients R1,
R2, and R5 progressed to AIDS after an asymptomatic follow-up
of 73, 112, and 72 months, respectively. Recipients R3 and R4
remained asymptomatic during the total follow-up period of 157
and 148 months, respectively.
The Amsterdam Cohort Studies are conducted in accordance
with the ethical principles set out in the declaration of Helsinki and
written consent was obtained prior to data collection. The study
was approved by the Academic Medical Center institutional
medical ethics committee.
HLA typing
Genotyping at HLA class I loci was performed by sequence
specific primers (SSP) PCR as described elsewhere [52].
Isolation of clonal HIV-1 variants
Clonal HIV-1 variants from single productively infected cells
were obtained by cocultivation of serial dilutions of PBMC that
were obtained around the moment of HIV-1 transmission from
both the donor and the recipient with 2–3 day phytohemagglu-
tinin stimulated PBMC from a healthy donor (PHA-PBMC) as
described previously [53]. To obtain PHA-PBMC, PBMC from a
healthy donor were cultured in IMDM supplemented with 10%
FCS (Hyclone), 1 mg/ml PHA (Welcome), Pen/Strep (Gibco Brl),
5 mg/ml Ciprofloxacin (Bayer) for 2–3 days in a culture flask at a
cell density of 5610
6/ml. Clonal virus variants were isolated by
cocultivation of 10,000–40,000 patient PBMC with 10
5 PHA-
PBMC in a final volume of 150 ml IMDM supplemented with
10% FCS (Hyclone), Pen/Strep (Gibco Brl), 10 U/ml rIL-2
(proleukin; Chiron Benelux BV), 5 mg/ml Ciprofloxacin (Bayer)
and 5 mg/ml polybrene (Sigma) for 35 days in a 96-well flat-
bottom microtiter plate. Every week, culture supernatants were
tested for virus production in an in-house Gag p24 antigen capture
enzyme-linked immunosorbent assay. At the same time, one-third
of the culture volume was transferred to new 96-well plate and
fresh PHA-stimulated healthy donor PBMC were added to
propagate the culture. If less than 1/3 of the microcultures per
patient-PBMC dilution were positive for p24 production, cultures
were considered to be infected by progeny of a single HIV infected
cell. A maximum of 10 clonal virus variants were expanded by
cocultivation of the cells from the microculture with 5610
6 PHA-
PBMC at a density of 1610
6/ml IMDM supplemented with 10%
FCS (Hyclone), Pen/Strep (Gibco Brl), 10 U/ml rIL-2 (proleukin;
Chiron Benelux BV), 5 mg/ml Ciprofloxacin (Bayer) and 5 mg/ml
polybrene (Sigma) in a culture flask.
DNA isolation, PCR amplification and sequencing
Total DNA was isolated from PBMC infected with clonal HIV-
1 isolates using the L6 isolation method [54]. Gag was amplified
using a nested polymerase chain reaction (PCR) with outer
primers Gag-forward (fw) (59-CGACGCAGGACTCGGCTTG-
CTG-39) and Gag-outer-reversed (rev) (59-GCCTGTCTCTCAG-
TAC-39) and 2 different sets of inner primers: Gag-BssHII-fw (59-
TGCTGAAGCGCCCGCACGGC-39) or Gag-ClaI-fw (59-GGG-
AGAATTAGATCGATGGG-39) in combination with Gag-p17-
rev (59-CAAAACTCTTGCCTTATGG-39) and Gag-p17-fw (59-
TGCTAAACACAGTGGGGGGACAT-39) in combination with
Gag-ApaI-rev (59-TTCCTAGGGGCCCTGCAA-39). Nef was
amplified using a nested PCR with outer primers Nef-1-fw (59-
AGCCATAGCAGTAGCTGAGG-39) and Nef-1-rev (59-GCTT-
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AGCTTGTAGAGCTATTCGCCACA-39) and Nef-2-rev (59-
AGCAAGCTCGATGTCAGCAG-39). Gag and Nef PCRs were
performed using Promega Taq polymerase in the presence of
2mM MgCl2 using the following amplification cycles: 2 min 95uC,
35 cycles of 30s 95uC, 30s 55uC, 2 min 72uC, followed by a
10 min extension at 72uC and subsequent cooling to 4uC.
Env was amplified using a nested PCR. The primary PCR was
perform with forward primer TB3 (59-GGCCTTATTAGGACA-
CATAGTTAGCC-39) and reverse primer TBC (59-GCTGC-
CTTGTAAGTCATTGGTCTTAAAGG-39) using the expand
high fidelity Taq polymerase kit (Roche) and the following
amplification cycles: 2 min 30s 94uC, 9 cycles of 15s 94uC, 45s
50uC, 2 min 72uC, 35 cycles of 15s 94uC, 45s 53uC, 2 min 72uC,
followed by a 10 min extension at 72uC and subsequent cooling to
4uC. Nested PCR was performed with 3 different sets of: seq1
(59-TACATAATGTTTGGGCCACACATGCC-39) and seq4
(59-CTTGTATTGTTGTTGGGTCTTGTAC-39); seq5 (59-GT-
CAACTCAACTGCTGTTAAATGGC-39) and seq6 (59-ATC-
TAATTTGTCCACTGATGGGAGG-39); PSCfw (59-ATCCT-
CAGGAGGGGACCCAGA-39) and PSH (59-CCATAGTGCT-
TCCTGCTGCT-39). Nested PCRs were performed using
Promega Taq polymerase in the presence of 2mM MgCl2 using
the following amplification cycles: 2 min 95uC, 35 cycles of 30s
95uC, 30s 55uC, 2 min 72uC, followed by a 10 min extension at
72uC and subsequent cooling to 4uC.
PCR products were purified using EXOSAP-IT (USB, Cleve-
land, Ohio, USA ) and sequenced using ABI prism Big Dye
Terminator v1.1 Cyclesequencing Kit (Applied Biosystems) using
the nested PCR primers. Sequences were analyzed on the Applied
Biosystems/Hitachi 3130 xl Genetic Analyzer.
HIV-1 RNA isolation from plasma, cDNA synthesis and
sequencing
From all recipients, plasma samples were available close to the
early (range 0–2 months later) and intermediate (range 12 month)
time points. From recipient R1 an additional plasma sample of the
late timepoint (54 months post SC) was available. Viral RNA was
isolated from plasma or serum using the QIAgen Viral RNA Mini
Kit and reverse transcribed into cDNA with Superscript II
RnaseH Reverse Transcriptase (Invitrogen) using outer primer
seq2 (59-TCCCTCATATCTCCTCCTCCAGGTC-39). cDNA
from the V3-V4 env region, derived from viral RNA in patient
plasma was amplified using nested PCR with the following primer
combinations: outer primers seq2 (59-TCCCTCATATCTCCT-
CCTCCAGGTC-39) and seq3 (59-TATGGGATCAAAGCCTA-
AAGCCATG-39), inner primers seq5 (59-GTCAACTCAACT-
GCTGTTAAATGGC-39) and seq6 (59-ATCTAATTTGTCCA-
CTGATGGGAGG-39). PCRs were performed using the following
amplification cycles: 5 min 94uC, 35 cycles of 45s 94uC, 30s 50uC,
90s 72uC, followed by a 6 min extention at 72uC and subsequent
cooling to 4uC. Bulk PCR products resulting from plasma RNA
were cloned in the pGEM-Teasy Vector system (Promega)
and transformed into DH5a competent cells (invitrogen). The
V3-V4 insert was amplified by PCR using primer pair seq5-seq6.
PCR products were purified using EXOSAP-IT (USB, Cleveland,
Ohio, USA ) and sequenced using the ABI prism Big Dye
Terminator v1.1 Cyclesequencing Kit (Applied Biosystems) using
the nested PCR primers. Sequences were analyzed on the Applied
Biosystems/Hitachi 3130 xl Genetic Analyzer.
Phylogenetic analysis
Sequences of env gp120 were manually aligned using ClustalW
included in the software package BioEdit [55] (BioEdit v 7.0.5, Tom
Hall, Ibis Therapeutics, Carlsbad, CA). The matrix of the aligned
sequences was imported into the tree building software PAUP* [56]
(http://paup.csit.fsu.edu/), and an initial neighbour-joining (NJ) tree
[57] was reconstructed under the Hasegawa-Kishino-Yano
(HKY85) model of evolution [58]. A heuristic search for a
maximum-likelihood tree, under time reversible model of nucleotide
substitution, with proportion of invariable sites and gamma rate
distribution was made. The robustness of the NJ phylogeny was
assessed by bootstrap analysis with 1,000 rounds of replication.
Prediction of CTL epitopes
Epitopes were predicted using motifscan in the Los Alamos
Database [59] in which deduced amino acid Gag, Env, and Nef
sequences were scanned for potential epitopes based on HLA
binding motifs (http://www.HIV-1.lanl.gov/).
Sequence analysis
Amino acid changes towards the consensus sequence of HIV-1
subtype B were considered reversions. Sequence changes away
from the subtype B HIV-1 consensus sequence, including escape
mutations in predicted CTL epitopes restricted by the HLA type
of the recipient, were considered forward mutations. When 4 or
more clonal HIV-1 variants from a single time point were
available for analysis, a reversion or forward mutations was
counted when the mutation was present in 50% or more of the
clonal HIV-1 variants. When less then 4 clonal HIV-1 variants
were isolated from a single time point during infection, an AA
change was considered a reversion or forward mutation only when
present in all viruses. The number of clonal HIV-1 variants that
were analysed per individual per timepoint is indicated in Table 2.
Supporting Information
Table S1 CTL escape mutations and reversions in HIV-1
variants isolated from HLA disparate pairs.
Found at: doi:10.1371/journal.pone.0002422.s001 (0.53 MB
DOC)
Figure S1 Phylogenetic analysis of env sequences of clonal HIV-
1 variants isolated from donors (D1-5) and recipients (R1-5)
involved in homosexual HIV-1 transmission. Shown is a
maximum likelihood tree with bootstrap values obtained from
neighbor joining analysis. Bootstrap values are given and show
that HIV-1 variants from donors and recipients are related.
Found at: doi:10.1371/journal.pone.0002422.s002 (0.35 MB TIF)
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